Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Genetic Analysis AS logo — We provide routine gut microbiome research and analysis base...

Genetic Analysis AS

We provide routine gut microbiome research and analysis based on our GA-map® platform and CE-IVD GA-map® Dysbiosis Test.

Founded 2008 Norway Norway 19 employees Venture round Total: $2.00M Biotechnology

General Information

Company Name Genetic Analysis AS
Founded Year 2008
Location Norway Norway
Employees 19
Industries Biotechnology
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Genetic Analysis AS. To contact Genetic Analysis AS, visit genetic-analysis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Genetic Analysis AS compare?

A PDF of Genetic Analysis AS and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Genetic Analysis AS soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Genetic Analysis AS

Genetic Analysis AS (GA) is a pioneering biotechnology startup based in Norway, established in 2008. Positioned as a global leader in molecular in-vitro diagnostics for diseases related to gut imbalances, GA leverages its patented DNA-based GA-map® platform technology to swiftly generate profiles of a patient’s gut microbiota. The flagship product, the GA-map® Dysbiosis Test, is geared toward Gastroenterologists, aiding in the assessment and monitoring of gut microbiota in patients with Irritable Bowel Syndrome (IBS). The pivotal offering has gained industry acclaim as the premiere commercially available, standardized, CE-marked, and clinically validated dysbiosis test, bolstered by 50 clinical trials and 30 publications, cementing its credibility. Notably, GA is actively engaged in exploring additional clinical applications in crucial areas such as diagnosis, disease severity course, treatment prediction, and monitoring for both IBS and IBD (inflammatory bowel disease), amplifying its impact in these domains. The company is also exploring opportunities in metabolic diseases, including type 2 diabetes. In October 2017, GA secured a significant $2.00M venture round investment led by Televenture, reflecting the market's confidence in the company's potential to drive innovation and advancement in the biotechnology sector. With a steadfast commitment to leveraging cutting-edge technology to address critical healthcare challenges, GA is poised for substantial growth and impact in the molecular in-vitro diagnostics landscape.

Business keywords: molecular diagnostics, genetic analysis, gut microbiome, DNA-based technology, inflammatory bowel disease, irritable bowel syndrome, CE-IVD GA-map® Dysbiosis Test, clinical validation, gastroenterology, metabolic disease, CE-marked, microbiota analysis, health conditions, data-driven diagnostics

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $2.00M 1
Televenture
Televenture
01 Oct 2017

Genetic Analysis AS Alternatives & Competitors

View All Alternatives
Genetic Analysis AS vs
Xbiome
Xbiome United States

China's leading AI-driven microbiome drug development company

Series B
51 employees
AI, Biotechnology
Genetic Analysis AS vs
PharmaBiome AG
PharmaBiome AG Switzerland

Pioneering the development of microbiome-based therapies using proprietary tools for their design an...

Convertible Note
11 employees
Biotechnology, Health Care
Genetic Analysis AS vs
DayTwo
DayTwo United States

Precision Nutrition for Metabolic Disease

16 employees
Biotechnology, Health Care
View all alternatives

FAQ About Genetic Analysis AS

We provide routine gut microbiome research and analysis based on our GA-map® platform and CE-IVD GA-map® Dysbiosis Test.
Genetic Analysis AS was founded in 2008.
Genetic Analysis AS is headquartered in Norway.
Genetic Analysis AS operates in Biotechnology. Its work centres on molecular diagnostics, genetic analysis, gut microbiome and DNA-based technology.
Genetic Analysis AS has approximately 19 employees.
Genetic Analysis AS has completed 1 funding round, raising a total of $2.00M. The latest funding stage is Venture round.
Top alternatives and competitors to Genetic Analysis AS include Xbiome, PharmaBiome AG, DayTwo, LCM Genect, Adela, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Genetic Analysis AS and Xbiome are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Genetic Analysis AS, https://bouncewatch.com/company/genetic-analysis-as, updated 29 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes